Investors

Investors

Leadership

Neumentum is led by a world-class executive team of biotech and pharmaceutical industry leaders who have extensive pain and neurology experience, from drug development through commercialization, and a cumulative 200+ years involvement with the most successful brands in the pain category (Lyrica, Celebrex, Nucynta, Lidoderm and others).

Pipeline

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company, and transforming how pain is treated–without opioids. The Company has 6 novel, non-opioid products in development to treat pain, both in the U.S. and around the world.

The portfolio includes 2 late-stage assets:
NTM-006

A late phase II, oral, once-daily, new chemical entity that is a non-opioid, non-NSAID, non-gabapentinoid analgesic with a novel MoA, in development for neuropathic/nociplastic conditions in the chronic pain market that is projected to grow to $29B by 2028.1

NTM-001

A phase III-ready, novel formulation of ketorolac (the most powerful NSAID), in a premixed bag forcontinuous infusion to deliver 24 hours of opioid level analgesia for postoperative pain, with potential 2022 approval and 2023 revenue.

Following development and approval, Neumentum’s medicines will provide patients, providers and payers a range of powerful non-opioid analgesics for safe and effective relief from pain–without the risks of addiction, abuse and misuse, nor the side effects and healthcare costs associated with opioids. These products will position the Company to capture significant share in the acute and chronic pain markets in both the hospital and community settings.

Investor Contacts

Patti Bank
Westwicke, an ICR company
patti.bank@westwicke.com

Scott Shively
CEO & Co-founder
scottshively@neumentum.com
(833) NEUPAIN

  1. DRG report, Disease Landscape & Forecast on Chronic Pain, June 2020

Disclaimer: These are investigational new drug candidates and are not approved for any indication in any market